Krsnaa Diagnostics Limited (KRSNAA)

About

Krsnaa Diagnostics runs diagnostic imaging and pathology centers across India. ₹1,863.97 Cr market cap, quarterly revenue ₹159–206 Cr. Operating margin 27.42% indicates stable profitability in organized diagnostics services.

Face value: ₹5

Market cap

₹1,798 Cr

P/E

18.4×

P/B

1.8×

Dividend yield

0.4%

ROE

10.9%

ROCE

13.1%

Debt / equity

0.55

OPM

27.4%

EPS (TTM)

₹30.0

Book value

₹302.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Stock down 31.12% over 12 months. Sector headwinds, execution issues, or fair-value revaluation? Identify which.

Net profit swings ₹15–43 Cr while revenue spans ₹159–206 Cr. One-time items, seasonal mix, or accounting variance? Verify before trusting earnings.

Operating margin fluctuates 25–32% across quarters. Track whether driven by pricing pressure, cost variance, or service-mix shifts.

Large national chains and e-commerce platforms entering diagnostics. Assess competitive intensity and Krsnaa's pricing power.

Generated analysis · source review pending

Growth drivers

Recent quarters show revenue ₹180–206 Cr (Sep 2025, Mar 2026), above ₹159 Cr floor—sustained momentum or cyclical?

Operating margin 27.42%, quarters peak 32.85% (Mar 2026). Pricing strength and cost discipline evident; identify if margin expansion repeatable.

D/E 0.55 provides lever for facility expansion typical in diagnostics. Verify capital allocation and deployment rate.

Net profit ₹43.38 Cr (Mar 2026), EPS ₹13.37. If sustained, earnings accretion could drive recovery from 31% YTD decline.

Generated analysis · source review pending

1,264 historical price candles were omitted because the exchange source has not been verified.

₹554.9+0.2%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 27.4%
+Profit CAGR of 17.8% over the last 3 years
+Revenue CAGR of 16.6% over the last 3 years

Cons

−Low return on equity of 9.1% (3-yr avg)
−Low dividend payout of 6.6% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

58/100

Business quality: 45
Growth: 54
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB	₹33,605 Cr	₹33,605 Cr	₹2,891 Cr	₹838 Cr	28.3%	₹542 Cr	18.5%	28.8%	21.6%	-79
Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA	₹14,694 Cr	₹14,694 Cr	₹857 Cr	₹362 Cr	41.4%	₹187 Cr	21.3%	21.3%	19.7%	-117
Metropolis Healthcare LimitedMETROPOLISMETROPOLIS	₹11,151 Cr	₹11,169 Cr	₹1,710 Cr	₹422 Cr	24.4%	₹202 Cr	11.6%	17.3%	13.4%	-57
Thyrocare Technologies LimitedTHYROCARETHYROCARE	₹8,495 Cr	₹8,495 Cr	₹876 Cr	₹282 Cr	31.6%	₹176 Cr	19.6%	36.5%	28.8%	4
Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS	₹6,509 Cr	₹6,589 Cr	₹999 Cr	₹227 Cr	22.7%	₹77 Cr	7.7%	17.1%	9.1%	-61
Suraksha Diagnostic LimitedSURAKSHASURAKSHA	₹1,824 Cr	₹1,826 Cr	₹325 Cr	₹102 Cr	30.7%	₹36 Cr	10.1%	16.8%	14.1%	-101
Krsnaa Diagnostics LimitedKRSNAAKRSNAA	₹1,798 Cr	₹2,332 Cr	₹815 Cr	₹218 Cr	27.4%	₹97 Cr	13.1%	13.1%	10.9%	65
3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO	₹1,416 Cr	₹1,417 Cr	₹96 Cr	₹50 Cr	52%	₹163 Cr	49.4%	25.3%	19.4%	235
One Global Service Provider LtdONEGLOBALONEGLOBAL	₹1,025 Cr	₹1,025 Cr	₹6 Cr	₹1 Cr	22.2%	₹1 Cr	17.3%	17.6%	19.5%	—
Health X Platform LimitedHEALTHXHEALTHX	₹868 Cr	₹890 Cr	₹1,468 Cr	₹-67 Cr	-4%	₹-20 Cr	-0.1%	—	0.2%	—
Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF	₹797 Cr	₹820 Cr	₹104 Cr	₹38 Cr	36.1%	₹24 Cr	23.4%	23.1%	16.1%	92
Aspira Pathlab & Diagnostics LtdASPIRAASPIRA	₹135 Cr	₹136 Cr	₹22 Cr	₹4 Cr	16%	₹2 Cr	9.2%	17.5%	18.1%	16

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	455	487	620	717	773
COGS	60	74	141	169	179
Gross profit	395	413	479	548	594
	264	291	334	358	382
	131	122	144	190	212
OPM %	28.9%	25.1%	23.3%	26.5%	27.4%
Depreciation	41	54	75	88	90
Interest	18	8	16	25	34
	15	19	17	26	43
Profit before tax	87	80	70	103	130
Tax	18	18	13	25	29
Tax %	21%	22.6%	18.8%	24.4%	22.2%
	68	62	57	78	101
PAT margin %	15%	12.8%	9.2%	10.8%	13.1%
EPS (₹)	22.9	19.8	17.9	24	31.3
EPS adjusted (₹)	21.8	19.8	17.6	24	31.3
	10.9%	13.9%	14%	11.4%	6.4%
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	16	16	16	16	16
Reserves	—	723	794	867	964
	—	32	160	204	534
	—	139	202	195	309
Total equity & liabilities	—	910	1,172	1,282	1,824
	386	471	647	670	656
CWIP	—	25	10	3	208
Investments	—	0	0	32	57
	—	413	515	577	902
Total assets	—	910	1,172	1,282	1,824

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	128	76	24	87	143
	-241	-109	-129	-100	-396
	176	-33	84	14	279
Net cash flow	64	-66	-20	1	26
Free cash flow	-4	-65	-170	-39	-76
CFO / Operating profit %	97.7%	62.4%	16.9%	45.9%	67.5%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	86.8%	84.8%	77.2%	76.4%	76.8%
EBITDA margin %	28.9%	25.1%	23.3%	26.5%	27.4%
EBIT margin %	19.8%	14.1%	11.2%	14.2%	15.7%
PAT margin %	15%	12.8%	9.2%	10.8%	13.1%
Working capital
Receivable days	—	55	104	141	140
Inventory days	—	123	93	64	54
Payable days	—	306	213	209	129
NWC days	—	-128	-17	-5	65
Leverage
Current ratio	—	2.28	1.5	1.36	2.68
Debt to EBITDA	—	0.27	1.11	1.07	2.52
Debt to equity	—	0.04	0.2	0.23	0.54
Interest coverage	5.7	11.4	5.2	5.2	4.8
Asset turnover	—	0.54	0.53	0.56	0.42
Return ratios
Return on assets %	—	6.8%	4.9%	6.1%	5.6%
Return on capital employed %	—	10.8%	10.2%	13.6%	13.1%
Return on equity %	—	8.4%	7%	8.8%	10.3%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	27.8%	27.03%	27.03%	27.17%	27.17%	27.24%	27.24%	27.11%	27.11%	27.11%	27.11%	27.11%
	3.68%	3.44%	3.34%	3.33%	3.63%	4.04%	3.55%	3.4%	3.67%	4.17%	3.91%	4.28%
	18.73%	16.58%	15.37%	15.26%	15.86%	14.46%	14.26%	14.24%	14.96%	13.86%	13.89%	14.51%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	49.79%	52.95%	54.26%	54.24%	53.34%	54.26%	54.95%	55.25%	54.26%	54.86%	55.09%	54.1%
No. of shareholders	—	—	—	—	—	—	—	—	52,117	52,380	53,022	53,625

Promoter holding down 0.69 percentage points since Sep 2023.

14 deals · 16 Aug 2021 – 15 Jun 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
15 Jun 2026	HDFC LIFE INSURANCE COMPANY LIMITED	Bulk	BSE	Sell	2,80,585	₹539.25	₹15.13 Cr
15 Jun 2026	HDFC LIFE INSURANCE COMPANY LIMITED	Bulk	BSE	Buy	2,80,585	₹539.25	₹15.13 Cr
12 Jun 2024	KITARA PIIN 1104	Bulk	NSE	Sell	3,72,000	₹600.69	₹22.35 Cr
3 Oct 2023	MEDIMAZE SOLUTIONS PRIVATE LIMITED	Block	NSE	Sell	1,50,000	₹675.00	₹10.13 Cr
3 Oct 2023	EAST LANE CAPITAL LLP	Block	NSE	Buy	1,50,000	₹675.00	₹10.13 Cr
28 Sept 2023	INVESCO MUTUAL FUND	Bulk	NSE	Sell	1,95,305	₹675.02	₹13.18 Cr
28 Sept 2023	MIV INVESTMENT SERVICES PRIVATE LIMITED	Bulk	NSE	Buy	1,59,909	₹675.00	₹10.79 Cr
9 May 2023	SOMERSET INDUS HEALTHCARE FUND I LIMITED	Bulk	NSE	Sell	8,90,857	₹495.27	₹44.12 Cr
9 May 2023	ACM GLOBAL FUND VCC	Bulk	NSE	Buy	6,90,857	₹495.25	₹34.21 Cr
16 Aug 2021	BIRLA SUN LIFE INSURANCE CO LTD	Bulk	NSE	Buy	2,30,000	₹1,023.34	₹23.54 Cr

1–10 of 14

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Rajendra MuthaExecutive Director-Chairperson
Mr. Yash MuthaExecutive Director-MD
Mr. Prem PradeepNon-Executive - Nominee Director
Mr. Chetan DesaiNon-Executive - Independent Director
Mr. Adesh Kumar GuptaNon-Executive - Independent Director
Mr. Raju VenkatramanNon-Executive - Independent Director
Ms. Lilian Jessie PaulNon-Executive - Independent Director
Mr. Mitesh DaveGroup Chief Executive Officer
Mr. Chandra Prakash SinghInterim Chief Financial Officer
Mr. Sujoy Sudipta BoseCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

8

across 3 fund houses

Held by these funds

8.21%

of the company's equity

All mutual funds

10.17%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

8 schemes · 3 fund houses

		Shares
SMALL CAP FUND	Tata Mutual Fund	26.08 L	144.4	1.1%	8.05%	-0
Multi Sector Rotation Fund	Shriram Mutual Fund	44,209	2.48	1.47%	0.136%	-0
Multi Asset Allocation Fund	Shriram Mutual Fund	2,630	0.15	0.1%	0.008%	-0
ELSS Tax Saver Fund	Shriram Mutual Fund	1,381	0.08	0.16%	0.004%	-0
Aggressive Hybrid Fund	Shriram Mutual Fund	940	0.05	0.1%	0.003%	-0
Balanced Advantage Fund	Shriram Mutual Fund	933	0.05	0.12%	0.003%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	498	0.03	0.06%	0.002%	-0
(Investment Manager for Motilal Oswal Mutual Fund)	Motilal Oswal Mutual Fund	54	0	0%	0%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

5

Credit ratings

1

Credit Rating29 Jun 2026

Investor Presentation and earnings call

5

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

5

Final dividend18 Sept 2026 · ex-date₹2
Final dividend12 Sept 2025 · ex-date₹2.75
Final dividend13 Sept 2024 · ex-date₹2.5
Final dividend15 Sept 2023 · ex-date₹2.75
Final dividend15 Sept 2022 · ex-date₹2.5

1

Board meeting to consider results13 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

62 announcementsExport CSV

11 Sept 2026, 2:01 pmCompany Update

Intimation - Regulation 36(1)(B) Of The SEBI Listing Regulations

General PDF

9 Sept 2026, 10:51 pmCompany Update

Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

General PDF

6 Sept 2026, 1:21 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

5 Sept 2026, 7:33 pmOthers

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting (BRSR) PDF

5 Sept 2026, 7:23 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

5 Sept 2026, 7:17 pmAGM/EGM

Notice Of 16Th Annual General Meeting Of Krsnaa Diagnostics Limited To Be Held On Monday, September 28, 2026 At 11:00 Hrs. (IST)

AGM PDF

2 Sept 2026, 12:14 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

29 Aug 2026, 1:45 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
11 Sept 2026, 2:01 pm	Company Update General	Intimation - Regulation 36(1)(B) Of The SEBI Listing Regulations	PDF
9 Sept 2026, 10:51 pm	Company Update General	Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Loading announcements…

Krsnaa Diagnostics Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

5

1

Announcements

Not in the F&O segment

5

1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Krsnaa Diagnostics Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends5

Board meetings1

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Dividends5

Board meetings1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

5

1

5

1